|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
20
|
|
pubmed:dateCreated |
2010-9-20
|
|
pubmed:abstractText |
Novel arylethynyltriazole acyclonucleosides were synthesized and assessed for their anticancer activity on drug-resistant pancreatic cancer MiaPaCa-2 cells. One lead compound was found to have much more potent apoptosis-related antiproliferative effects than gemcitabine, the current first-line treatment for pancreatic cancer. Further investigations showed that this active compound did not inhibit DNA synthesis, which means that it does not resemble gemcitabine and may involve a different mechanism of action.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1464-3405
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5979-83
|
|
pubmed:meshHeading |
pubmed-meshheading:20829040-Antineoplastic Agents,
pubmed-meshheading:20829040-Cell Line, Tumor,
pubmed-meshheading:20829040-Cell Proliferation,
pubmed-meshheading:20829040-Deoxycytidine,
pubmed-meshheading:20829040-Drug Resistance, Neoplasm,
pubmed-meshheading:20829040-Humans,
pubmed-meshheading:20829040-Nucleosides,
pubmed-meshheading:20829040-Pancreatic Neoplasms,
pubmed-meshheading:20829040-Triazoles
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
A novel arylethynyltriazole acyclonucleoside inhibits proliferation of drug-resistant pancreatic cancer cells.
|
|
pubmed:affiliation |
State Key Laboratory of Virology, College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, PR China.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
